Literature DB >> 7527739

Antigenic structure of the hepatitis C virus envelope 2 protein.

Z X Zhang1, A Sönnerborg, M Sällberg.   

Abstract

The antigenic structure of the envelope 2 (e2) protein of the hepatitis C virus (HCV) was characterized by the use of 70 synthetic peptides and 131 human sera from persons with antibodies to HCV. Among 34 overlapping peptides spanning the e2 protein of HCV, two major antigenic regions were located to residues 484-499 and residues 554-569. The sequence of the two major antigenic regions of the e2 protein are partly well conserved within the described types of HCV. Both regions contain two Cys residues in close proximity, and the region at residues 554-569 contains a putative N-glycosylation site, which are factors that previously have been suggested to affect the immune recognition of the e2 protein. Using substitution peptide analogues where each position within residues 484-499 and 554-569 were sequentially substituted by Ala or Gly, the most essential residues for antibody binding were found to be the Pro-498, Ala-499, Ala-566, Pro-567, and Pro-568. All of these, except for the Pro-498 and Ala-566, are conserved among different HCV strains. Also, according to previous studies, position 496 often shows variations, which could be explained by position 496 being contained within the antigenic region at residues 484-499. Interestingly, none of the Cys residues at positions 486, 494, 564 and 569 were found to be essential for antibody binding, indicating that these are not essential in maintaining the e2 antigenicity of the peptides. In a material of 114 confirmed anti-HCV positive sera, derived from patients during the acute or the chronic phase of HCV infection, the prevalence of antibodies to the two major linear antigenic regions of the e2 protein was found to be 55% among HCV RNA-positive sera, and 53% among HCV RNA-negative sera. In conclusion, we have identified and characterized two major linear antigenic regions outside the two hypervariable regions of the e2 protein. Since these regions are accessible to the B cells of the infected host, these two regions are likely to be surface exposed either on the precursor polyprotein or the native e2 protein. Also, we could confirm that antibodies to the e2 protein co-exist with HCV viraemia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7527739      PMCID: PMC1534497          DOI: 10.1111/j.1365-2249.1994.tb05501.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  37 in total

1.  Detection of antibodies to hepatitis C virus (HCV) structural proteins in anti-HCV-positive sera by an enzyme-linked immunosorbent assay using synthetic peptides as antigens.

Authors:  C Ishida; K Matsumoto; K Fukada; K Matsushita; H Shiraki; Y Maeda
Journal:  J Clin Microbiol       Date:  1993-04       Impact factor: 5.948

2.  Antigenic regions within the hepatitis C virus envelope 1 and non-structural proteins: identification of an IgG3-restricted recognition site with the envelope 1 protein.

Authors:  M Sällberg; U Rudén; B Wahren; L O Magnius
Journal:  Clin Exp Immunol       Date:  1993-03       Impact factor: 4.330

3.  Characterization of hypervariable regions in the putative envelope protein of hepatitis C virus.

Authors:  N Kato; Y Ootsuyama; S Ohkoshi; T Nakazawa; H Sekiya; M Hijikata; K Shimotohno
Journal:  Biochem Biophys Res Commun       Date:  1992-11-30       Impact factor: 3.575

4.  Immune response to a single peptide containing an immunodominant region of hepatitis C virus core protein: the isotypes and the recognition site.

Authors:  M Sällberg; U Rudén; B Wahren; L O Magnius
Journal:  Immunol Lett       Date:  1992-06       Impact factor: 3.685

5.  Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability.

Authors:  H Okamoto; M Kojima; S Okada; H Yoshizawa; H Iizuka; T Tanaka; E E Muchmore; D A Peterson; Y Ito; S Mishiro
Journal:  Virology       Date:  1992-10       Impact factor: 3.616

6.  Lack of protective immunity against reinfection with hepatitis C virus.

Authors:  P Farci; H J Alter; S Govindarajan; D C Wong; R Engle; R R Lesniewski; I K Mushahwar; S M Desai; R H Miller; N Ogata
Journal:  Science       Date:  1992-10-02       Impact factor: 47.728

7.  Diagnosis of hepatitis C virus (HCV) infection using an immunodominant chimeric polyprotein to capture circulating antibodies: reevaluation of the role of HCV in liver disease.

Authors:  D Y Chien; Q L Choo; A Tabrizi; C Kuo; J McFarland; K Berger; C Lee; J R Shuster; T Nguyen; D L Moyer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

8.  Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites.

Authors:  A Grakoui; D W McCourt; C Wychowski; S M Feinstone; C M Rice
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

9.  Expression and identification of hepatitis C virus polyprotein cleavage products.

Authors:  A Grakoui; C Wychowski; C Lin; S M Feinstone; C M Rice
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

10.  Molecular cloning of hepatitis C virus genome from a single Japanese carrier: sequence variation within the same individual and among infected individuals.

Authors:  T Tanaka; N Kato; M Nakagawa; Y Ootsuyama; M J Cho; T Nakazawa; M Hijikata; Y Ishimura; K Shimotohno
Journal:  Virus Res       Date:  1992-04       Impact factor: 3.303

View more
  1 in total

1.  Clustering of rare peptide segments in the HCV immunome.

Authors:  Angela Stufano; Giovanni Capone; Barbara Pesetti; Lorenzo Polimeno; Darja Kanduc
Journal:  Self Nonself       Date:  2010-02-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.